Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next-Generation Sequencing Bioinformatics and Variant Interpretation by Davies, Kurtis D. et al.
The Journal of Molecular Diagnostics, Vol. 18, No. 4, July 2016jmd.amjpathol.orgSee related Commentary on page 469Multi-Institutional FASTQ File Exchange as a
Means of Proficiency Testing for Next-Generation
Sequencing Bioinformatics and Variant Interpretation
Kurtis D. Davies,* Midhat S. Farooqi,y Mike Gruidl,z Charles E. Hill,x Julie Woolworth-Hirschhorn,{ Heather Jones,x
Kenneth L. Jones,k Anthony Magliocco,z Midori Mitui,y Philip H. O’Neill,k Rebecca O’Rourke,k Nirali M. Patel,** Dahui Qin,z
Erica Ramos,y Michael R. Rossi,x Thomas M. Schneider,x Geoffrey H. Smith,x Linsheng Zhang,x Jason Y. Park,y and
Dara L. Aisner*From the Departments of Pathology* and Biochemistry and Molecular Genetics,k University of ColoradoeAnschutz Medical Campus, Denver, Colorado; the
Department of Pathology,y Children’s Health & UT Southwestern Medical Center, Dallas, Texas; the Pathology Department,z H. Lee Moffitt Cancer Center,
Tampa, Florida; the Department of Pathology and Laboratory Medicine,x Emory University School of Medicine, Atlanta, Georgia; the Department of
Pathology and Laboratory Medicine,{ Medical University of South Carolina, Charleston, South Carolina; and the Department of Pathology and Laboratory
Medicine,** University of North Carolina School of Medicine, Chapel Hill, North CarolinaAccepted for publicationC
hMarch 14, 2016.
Address correspondence to
Dara L. Aisner, M.D., Ph.D.,
Department of Pathology, Uni-
versity of ColoradoeAnschutz
Medical Campus, 12631 E.
17th Ave., Mail Stop B-216,
L15-2215, Aurora, CO 80045.
E-mail: dara.aisner@ucdenver.
edu.opyright ª 2016 American Society for Inve
ttp://dx.doi.org/10.1016/j.jmoldx.2016.03.002Next-generation sequencing is becoming increasingly common in clinical laboratories worldwide and is
revolutionizing clinical molecular testing. However, the large amounts of raw data produced by next-
generation sequencing assays and the need for complex bioinformatics analyses present unique chal-
lenges. Proficiency testing in clinical laboratories has traditionally been designed to evaluate assays in
their entirety; however, it can be alternatively applied to separate assay components. We developed and
implemented a multi-institutional proficiency testing approach to directly assess custom bioinformatics
and variant interpretation processes. Six clinical laboratories, all of which use the same commercial
library preparation kit for next-generation sequencing analysis of tumor specimens, each submitted raw
data (FASTQ files) from four samples. These 24 file sets were then deidentified and redistributed to five
of the institutions for analysis and interpretation according to their clinically validated approach.
Among the laboratories, there was a high rate of concordance in the calling of single-nucleotide
variants, in particular those we considered clinically significant (100% concordance). However, there
was significant discordance in the calling of clinically significant insertions/deletions, with only two of
seven being called by all participating laboratories. Missed calls were addressed by each laboratory to
improve their bioinformatics processes. Thus, through our alternative proficiency testing approach, we
identified the bioinformatic detection of insertions/deletions as an area of particular concern for
clinical laboratories performing next-generation sequencing testing. (J Mol Diagn 2016, 18: 572e579;
http://dx.doi.org/10.1016/j.jmoldx.2016.03.002)Supported by institutional funding with additional support provided by
the Colorado Center for Personalized Medicine (University of Colorado).
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prognostic, or diagnostic clinical significance increases,
there is an increasing need for robust clinical assays that
detect multiple alterations simultaneously.1 Next-generation
sequencing (NGS) technology is uniquely positioned to
meet this increasing demand attributable to the ability to
generate nucleic acid sequence data on multiple analytes in
parallel, with the potential for high clinical throughput. As a
result, NGS is becoming the platform of choice in many
clinical settings. However, in contrast to traditional geneticstigative Pathology and the Association for Massays that are designed to detect only one or a few genetic
variants, NGS assays involve multifaceted workflows and
produce massive amounts of raw data that require complex
bioinformatics (BI) handling and analysis.olecular Pathology. Published by Elsevier Inc. All rights reserved.
FASTQ-Based NGS Proficiency TestingNGS testing of clinical samples is typically divided into
several distinct subprocesses. Initially, evaluation of the
specimen by a pathologist often guides enrichment of the
desired tissue type, which is then subjected to nucleic acid
extraction. Extracted nucleic acids are then made ready for
sequencing through various library preparation techniques,
with libraries subsequently being quantified and pooled
accordingly. Pooled libraries are then sequenced on an NGS
sequencing instrument via unique chemical processes,
depending on the platform. Sequencing is followed by a
highly computationally dependent workflow that includes
conversion of raw signals to base calls and short sequence
reads (usually performed by on-instrument software),
demultiplexing of pooled data (also typically by on-
instrument software), alignment/mapping of the reads to
the reference genome, calling of variants that differ from the
reference genome, and annotation of the identified vari-
ants.2,3 Involved in all of these computational steps are
filters and quality control (QC) cutoffs that remove poor
quality data and reject data deemed to be erroneous or
artifactual. This system of BI tools and QC measures is
often called the BI pipeline, and it can vary markedly among
laboratories owing to the different software components
used for each step, customization of these programs, and the
different QC metrics used. Finally, the large amount of
variant data produced is often manually interpreted with
the aid of available databases and other resources, and,
again, these manual steps can be dissimilar among different
laboratories. Validation of the postsequencing processes
(computational and interpretation steps) is part of any NGS
assay validation; however, external metrics for assuring
quality of BI pipelines and interpretation procedures can be
challenging to identify. Nevertheless, it is critical that the
performance of postsequencing steps is evaluated as part of
ongoing laboratory quality management.3
Proficiency testing (PT) is a vital aspect of clinical lab-
oratory quality management.4 Although PT is common for
wet-bench procedures and usually includes the entire assay
process, it is less widespread for the postsequencing steps of
NGS because of the nascent nature of this technology.5 We
determined the feasibility of a postsequencing-focused PT
approach and assessed differences in the performance of BI
pipelines and interpretative processes used by different in-
stitutions. Twenty-four raw data (FASTQ) file sets gener-
ated by NGS analysis of samples processed using a common
library preparation kit were aggregated, deidentified, and
distributed to five institutions. These files were then
analyzed by each institution’s validated postsequencing
procedures, and each institution reported variants as they
would for a clinical case. Concordance of findings was then
assessed and discordant variants explored further. The
identification of single-nucleotide variants (SNVs), in
particular those that are clinically significant (cs-SNVs), was
concordant among all institutions, with highly consistent
reported variant allele frequencies (VAFs). However, the
identification of clinically significant insertions/deletionsThe Journal of Molecular Diagnostics - jmd.amjpathol.org(cs-indels) was substantially less concordant, with many
instances of such variants being missed by some BI pipe-
lines. Thus, we demonstrate the feasibility of FASTQ file
exchange as a means of performing PT and highlight key
areas of concern for clinical BI pipelines.
Materials and Methods
Study Sites
All six clinical laboratories that participated in this study are
Clinical Laboratory Improvement Amendments certified
(Centers for Medicare & Medicaid Services) and accredited
by the College of American Pathologists (CAP). The
sequencing assay examined in this study was independently
validated and implemented by each laboratory. All labora-
tories registered their NGS activity with CAP.
Library Preparation
The TruSight Tumor (TST) library preparation kit (Illumina,
San Diego, CA) was separately clinically validated and
implemented by all institutions in this study. TST is an
amplicon-based assay designed to selectively amplify hot-
spots, exons, or entire coding regions of 26 genes important
for prognosis or therapy selection for patients with cancer.
Each amplicon is generated via an extension-ligation process
that links two primers that are complimentary to the same
strand. The assay uses a dual strand approach by which both
strands of every region of interest are amplified in separate
library preparations, giving rise to two pools: A and B. These
pools are uniquely indexed and can be distinguished from
each other on the sequencing run. The presence of a variant in
both pools increases the reliability of the variant calls and
aids in filtering out artifacts (eg, those due to formalin fixation
or PCR errors). All sites performed sequencing on the
Illumina MiSeq instrument using V2 sequencing chemistry
and paired-end 121-bp reads. FASTQ files were generated
via on-board MiSeq Control software versions 2.0, 2.0.5, and
2.5.0.5 (Illumina), and MiSeq Reporter software versions 2.3,
2.4.1.3, 2.4.6, and 2.5.1.3 (Illumina).
File Submission, Redistribution, and Analysis
Each site initially completed a survey on the specific aspects
of both the wet-bench steps of their assay and the various
components and QC metrics of their BI pipeline and variant
interpretation processes. Survey questions included the
number of samples multiplexed per flow-cell, minimum
read depth cutoff requirements, and VAF cutoffs, among
others (Table 1). All sites then submitted sets of FASTQ
files from four previously run samples, with specific re-
quests that a range of tumor types be represented and that
each site include at least one file set from a sample
harboring an indel. Files were uploaded to a single institu-
tion via a secure File Transfer Protocol site. Participants also573
Table 1 Survey Characteristics
Characteristic
Site
1 2 3 4 5 6*
Samples per flow
cell (combined A
and B pools)
8 4 8 maximum 10 2e10 Up to 13
Required minimum
depth of
coverage
(combined pools)
500 1000 2000 1000 1000 1000
VAF cutoff for
inclusion in
report
5%y 5% 3%y 5% 5% 5%
Indel size limit (bp) 40 Not determined 15 Not determined 30 25
Alignment software GSNAP version
7.20.2012
NextGENe version
2.4.1
(SoftGenetics,
State College, PA),
MiSeq Reporter
version 2.4.60
NovoAlign version
3.02.00
(NovoCraft
Technologies,
Selangor,
Malaysia)
BWA-MEM version
0.7.12 (Broad
Institute,
Cambridge, MA)
NextGENe version
2.4.1, MiSeq
Reporter version
2.4.1.3
MiSeq Reporter
version 2.3
Variant calling
software
Freebayes version
0.9.14
NextGENe version
2.4.1, MiSeq
Reporter version
2.4.60
SNVseVarScan
version 2.3.6
(Washington
University, St.
Louis, MO)
IndelseFreebayes
version 0.9.7
GATK version 3.4
(Broad
Institute)
NextGENe version
2.4.1, MiSeq
Reporter version
2.4.1.3
MiSeq Reporter
version 2.3
Variant annotation ANNOVAR version
10.23.2012,
dbNSFP version
2.0b4
Geneticist Assistant
version 1.1.5
(Softgenetics)
Clinical Genomicist
Workstation
version 2.1.3
(PerianDX, St.
Louis, MO)
ANNOVAR version
3.22.15
Variant Studio
version 2.1
(Illumina),
NextGENe
version 2.4.1
Variant Studio
version 2.1
Databases for
variant
interpretation
COSMIC, ClinVar,
My Cancer
Genome,
cBioPortal,
MD Anderson
PCT, CanDL
HGMD, COSMIC, My
Cancer Genome,
ClinVar
COSMIC, ClinVar,
Clinical
Genomicist
Workstation
COSMIC,
cBioPortal, My
Cancer
Genome,
ClinVar
HGMD, COSMIC,
My Cancer
Genome, ClinVar
HGMD, COSMIC,
My Cancer
Genome,
ClinVar, MD
Anderson PCT
Databases for
polymorphism
determination
1000 Genomes,
dbSNP
1000 Genomes,
NHLBI ESP
dbSNP, NHLBI ESP 1000 Genomes 1000 Genomes,
NHLBI ESP
1000 Genomes,
NHLBI ESP
ANNOVAR is available at http://annovar.openbioinformatics.org/en/latest/misc/credit; GSNAP, http://research-pub.gene.com/gmap; Freebayes, http://arxiv.
org/abs/1207.3907; dbNSFP, https://sites.google.com/site/jpopgen/dbNSFP.
*Site did not participate in file analysis.
yCan be lowered at the medical director’s discretion.
Davies et alindicated the sample type (eg, formalin-fixed, paraffin-
embedded), tumor histology, tumor location, estimated
sample tumor percentage, and percentage of necrosis for
each sample. The 24 FASTQ file sets (96 total files because
each case was represented by A and B pools and each pool
represented by R1 and R2 reads) were deidentified by an
individual not associated with this project and then redis-
tributed via the secure File Transfer Protocol site along with
a reporting template that listed the sample-specific infor-
mation stated above (including whether the file set was from
a calibrator/reference sample). One site (site 6), which
contributed two of the indel cases, including the EGFR574duplication and the ERBB2 duplication, was not equipped to
analyze externally provided FASTQ files and did not
participate in any of the analytical components of this study.
The five participating institutions were asked to analyze all
the files (including the files, now deidentified, that they had
submitted) via their own BI pipeline and to report all vari-
ants that would be reported for a clinical case. Participants
were also asked to provide their determined VAF for each
identified variant, regardless of whether this is part of their
usual reporting practice. A summary of all reported variants
per sample was then generated and redistributed to the sites,
which were then asked to provide an explanation for everyjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 1 Sample characteristics. A: Of the 24 sample file sets used in
the proficiency test, 20 were derived from formalin-fixed, paraffin-
embedded (FFPE) processed clinical samples, one was derived from a
Diff-Quik slide processed clinical sample, and three were derived from
commercially available calibrators (NA12878, HD129, and HD200). B:
Disease type distribution for the 21 clinical samples. C: Distribution of the
total number of variants (summary of all variants called by all institutions)
reported per sample, including calibrator samples.
FASTQ-Based NGS Proficiency Testingvariant that they did not report but that at least one other
institution did report. Additional information was solicited
regarding BI improvements made as a result of this PT.Results
The six institutions that participated in this study all use the
Illumina TST library preparation kit in combination with the
Illumina MiSeq instrument for molecular analysis of clinical
tumor samples. The TST kit amplifies selected hotspots,
exons, or entire coding regions of 26 genes that have clinical
relevance for various cancer types.6,7 Although this com-
mon library preparation method was used, some differences
in the wet-bench components of the assay existed among the
institutions, most notable of which were dissimilarities in
the number of samples included on each sequencing run
(range, 2 to 13 samples per run) (Table 1). Each of the six
institutions submitted FASTQ files [generated via on-board
MiSeq instrument software (see Materials and Methods)
from raw image data] for four samples previously run in-
house, resulting in file sets for 24 samples (96 separate
FASTQ files because each sample has separate A and B
pools and each pool is represented by R1 and R2 reads). Of
these, 21 were derived from clinical tumor samples (from a
variety of cancer types) and three from commercially
available calibrator/reference samples (Figure 1, A and B).
The institutions were encouraged to submit at least one case
that contained an indel because these variants are known to
be particularly challenging for BI pipelines.3,8 The 24 file
sets were then deidentified and distributed to five of the
institutions. One site (site 6) did not participate in file analysis
because it uses on-board MiSeq Reporter software versionThe Journal of Molecular Diagnostics - jmd.amjpathol.org2.3 and Variant Studio version 2.1 exclusively and was not
equipped to analyze externally provided FASTQ files.
Each of the five participating institutions then analyzed
all 24 file sets via their own BI pipeline and interpretive
processes. The components of the pipelines differed among
the institutions with various combinations of tools for
alignment (GSNAP, NextGENe, MiSeq Reporter, Novo-
Align, BWA-MEM), variant calling (Freebayes, NextGENe,
MiSeq Reporter, VarScan, GATK), and variant annotation
(ANNOVAR, dbNSFP, Geneticist Assistant, Clinical
Genomicist Workstation, Variant Studio, NextGENe) used
(Table 1). In addition, each institution used its own QC
metric cutoffs, most notably for minimum read depth (range,
500 to 2000 for the combined A and B pools, with some
institutions also using per pool minimums) and VAF
threshold for positive variant identification [range, <3% (at
the medical director’s discretion) to 5%] (Table 1).
Finally, the resources and databases used for variant inter-
pretation and polymorphism determination varied among
the institutions (Table 1). Thus, there were marked differ-
ences among the institutions in regard to the BI pipeline
components, QC metrics, and interpretive tools used.
After analysis, the institutions were asked to report vari-
ants as they would for a clinical case based on the tumor
type information provided. These reports were then com-
bined to generate a complete list of called variants to be
used for concordance analysis. To simplify this analysis and
because of feasibility constraints, synonymous and intronic
variants were excluded. The range of total reported non-
synonymous and exonic variants per sample for all 24
samples is shown in Figure 1C.
Among the 21 clinical cases, a total of 48 variants were
included in calls by the five institutions. Of these, 16 were575
≤1%
>1% to ≤5%
>5% to ≤10%
>10%
Figure 2 Variant allele frequency (VAF) concordance. The range of VAF
(highest reported minus lowest reported) was calculated for all variants
reported by at least two institutions (66 variants total). The distribution of
these ranges is shown. The VAF range was 5% for most variants (81.8%).
Table 2 Summary of the SNVs
Alteration type
No. (%) of sites
that made call
(if sample passed QC)
All clinically significant SNVs* (n Z 9) All 5/5 (100)
SNVs with uncertain clinical significance (n Z 29)
22 Variants called by all sites 4/4 or 5/5 (100)
4 Variants for which 1 site did not call 3/4 or 4/5 (75 or 80)
1 Variant for which 2 sites did not call 2/4 or 3/5 (50 or 60)
2 Variants for which 3 sites did not call 1/4 or 2/5 (25 or 40)
Clinically significant insertions/deletions* (n Z 7)
KIT c.1729_1746dupCCTTATGATCACAAATGG 2/4 (50)
EGFR c.2240_2257delTAAGAGAAGCAACATCTC 4/5 (80)
EGFR c.2235_2249delGGAATTAAGAGAAGC 5/5 (100)
EGFR c.2235_2249delGGAATTAAGAGAAGC 3/4 (75)
EGFR c.2235_2249delGGAATTAAGAGAAGC 4/4 (100)
EGFR c.2304_2318dupCGTGGACAACCCCCA 2/5 (40)
ERBB2 c.2311_2322dupGCATACGTGATG 4/5 (80)
Indels with uncertain clinical significance (n Z 3)
2 Variants for which 1 site did not call 3/4 (75)
1 Variant for which 2 sites did not call 3/5 (60)
Variants in calibrator samples (SNVs and indels) (n Z 20)
13 Variants called by all sites 5/5 (100)
3 Variants for which 1 site did not call 4/5 (80)
2 Variants for which 2 sites did not call 3/5 (60)
1 Variant for which 3 sites did not call 2/5 (40)
1 Variant for which 4 sites did not call 1/5 (20)
*Variants were deemed clinically actionable if known to influence clinical
decision for stated disease type.
QC, quality control; SNV, single-nucleotide variant.
Davies et aldeemed to be clinically significant variants, whereas 32
were deemed variants of uncertain significance (VUSs).
Clinical significance was determined on a variant by variant
basis, taking disease type into account, and this determina-
tion was based on a consensus opinion of study leaders to
avoid an additional layer of complexity in reporting the data.
One of the institutions applied a QC metric that deemed an
entire sample a QC fail if any targeted region within the
assay was covered by <1000 for the combined pools or by
<300 for either of the individual pools. When this
occurred, this institution was not included in the concor-
dance assessment for a particular variant (ie, the denomi-
nator was changed from 5 to 4). A total of 38 SNVs were
reported, 31 of which (81.6% concordance) were called by
all participating sites (Table 2). All nine cs-SNVs were
called by all five institutions (100% concordance). Of the 29
VUS SNVs, 22 were called by all participating sites (75.9%
concordance). For the remaining seven VUS SNVs, there
were four for which one participating site did not call, one
for which two sites did not call, and two for which three
sites did not call (Table 2). In addition, 10 indels were re-
ported, with only two being called by all participating sites
(20% concordance). Seven of the indels (all of which were
>10 bp) were deemed clinically significant, and only two of
the seven were called consistently (28.6% concordance). Of
note, only two of the five sites (sites 1 and 4) reported all
seven cs-indels. For several of these, orthogonal testing
confirmed the presence of the indel. Three VUS indels were576also reported (all <10 bp), two of which were not called by
one participating site and one of which was not called by
two sites (Table 2).
Concordance of variant calls from calibrator samples (all
of which were SNVs and small indels) is also listed in
Table 2. The calibrator samples included in this study were
NA12878 (Coriell Institute, Camden, NJ), HD129 (Horizon
Discovery, Cambridge, UK), and HD200 (Horizon Dis-
covery), for which there were 0, 4, and 16 combined vari-
ants calls, respectively. Of these, 13 variants were called by
all five sites, three variants were called by four of five sites,
two variants were called by three of five sites, one variant
was called by two of five sites, and one variant was called
by one of five sites.
Including clinical samples and calibrator samples, there
were 68 total variants reported. Two of these 68 variants, a
KIT c.1676T>C SNV (reported at 3% VAF) and a MSH6
c.3254dupC (described by three sites as a persistent assay
artifact), were only reported by one institution, but the
remaining 66 were assessed for VAF concordance by
calculating the range of reported VAFs (highest reported
minus lowest reported). Remarkably, this range was 1%
for 40 (60.6%) and 5% for 54 (81.8%) of the variants
reported (Figure 2). Eight variants (12.1%) were reported at
ranges >5% and 10%, and only four variants (6.1%) were
reported at VAF ranges >10%. The largest VAF range
observed for a variant was 34% to 52% (range of 18%),
which was seen for a PIK3CA c.3140A>G mutation re-
ported by all five institutions. The explanation for this large
range in percentage of VAF likely involves the fact that this
position is at a primer binding site in the TST assay.
After the concordance analysis, a summary of all variants
identified for each sample was then redistributed to each
site. The sites were then asked to provide an explanation for
every call that they did not make but that at least one other
site made. Explanations were limited to a drop-down menu
of choices, including failed QC, below VAF cutoff,
persistent assay artifact, technical concern, SNP (meaning
an SNV deemed to be benign based on inherited allelejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 Summary of the Reasons for Noncall and Discordance
Cited reason for noncall No. of instances
Clinical samples
Failed QC 12
Below VAF cutoff 4
Technical concern 3
SNP 8
Variant not detected by BI algorithm 9
Calibrator samples
Below VAF cutoff 3
Persistent assay artifact 3
SNP 1
Variant not detected by BI algorithm 7
BI, bioinformatics; QC, quality control; SNP, single-nucleotide poly-
morphism; VAF, variant allele frequency.
FASTQ-Based NGS Proficiency Testingfrequency and protein coding effect), or variant not identi-
fied by BI algorithm. For the 21 clinical cases, the reasons
given for noncalls are tabulated in Table 3. Twelve instances
of failed QC for a variant noncall were reported. However,
as detailed above, all 12 were reported by a single institution
that rejected the sample as a whole if any region did not
meet minimum coverage metrics (in other words failed QC
indicates rejection of all the data for the sample and does not
necessarily indicate that the variant itself was not detected).
Aside from these failed QC cases, there were four instances
of noncalls due the variant being below VAF cutoff, three
instances of technical concern, eight instances of a variant
being deemed SNP, and nine instances of variant not
identified by BI algorithm. Importantly, for the clinical
samples, the only instances of discordance that could be
strictly attributed to manual interpretation of the data were
the eight occasions in which a variant was deemed an SNP.
Reasons for discordance in the calibrator samples are also
listed in Table 3.
Because the reporting of cs-indels was highly discordant
among the institutions, we explored the reasons behind
these discrepancies in greater detail (Table 4). The KIT
c.1729_1746dupCCTTATGATCACAAATGG exon 11
insertion (which was confirmed by Sanger sequencing) was
only called by two institutions (at 36% and 41% VAF). One
site did not call the variant due to failed QC for the sample
as a whole. Another site reported the noncall as a technical
concern. When this institution investigated this case further,
it was discovered that the duplication was present but beingTable 4 Summary of the Reasons for Noncall
Indel VAF range (%) Cited
KIT c.1729_1746dupCCTTATGATCACAAATGG 36e41 Failed
EGFR c.2240_2257delTAAGAGAAGCAACATCTC 22e24 Not id
EGFR c.2235_2249delGGAATTAAGAGAAGC 40e48 Identi
EGFR c.2235_2249delGGAATTAAGAGAAGC 14e18 Failed
EGFR c.2235_2249delGGAATTAAGAGAAGC 81e86 Failed
EGFR c.2304_2318dupCGTGGACAACCCCCA 29e30 Not id
ERBB2 c.2311_2322dupGCATACGTGATG 34e40 Techn
BI, bioinformatics; QC, quality control; VAF, variant allele frequency.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgcalled as substitutions by the pipeline. Furthermore, there
was a low number of reads harboring the duplication, and
these were of low quality (suggesting that perhaps many of
reads were eliminated before mapping). The other institution
that missed this variant reported it as variant not identified
by BI algorithm. On further investigation it was discovered
that the pipeline technically detected the insertion but that
stringent BI filters resulted in it not being reported. With
adjustment of these filters, the insertion was detected and
reported.
Four of the seven cs-indels were EGFR exon 19 de-
letions. One of these, c.2240_2257delTAAGAGAAGCA-
ACATCTC, was called by four of the five institutions with
the remaining institution citing variant not identified by
BI algorithm. This false-negative result prompted the insti-
tution, which uses the NovoAlign alignment tool, to update
to a newer version of the software and modify the indel
detection scripts. After these changes were made, the indel
was detected by the institution’s BI pipeline. The remaining
three EGFR exon 19 deletions were all c.2235_2249delG-
GAATTAAGAGAAGC. For one of these (reported VAF
range, 40% to 48%), all five institutions detected the variant.
For another (VAF range, 81% to 86%), the presence of
which was confirmed by pyrosequencing, one institution
reported failed QC for the entire sample, but the remaining
four institutions detected the variant. In the third instance,
the VAF range was 14% to 18%, and the deletion was
confirmed by Sanger sequencing. Again, one institution
reported failed QC for the entire sample. Another institution
did not report the variant because of it being below the VAF
cutoff (10%). In this instance, the variant was observed at
9% VAF, but this indel was not established within the in-
stitution’s pipeline as a hotspot variant. In this particular
pipeline, designation as a hotspot effectively increases
sensitivity by reducing the VAF threshold for the variant.
Adding this deletion as a hotspot in the pipeline resulted in
its identification.
Another particularly challenging cs-indel in this study
was an EGFR exon 20 duplication (c.2304_2318dupCG-
TGGACAACCCCCA), which was confirmed by Sanger
sequencing. Only two of the five institutions identified the
variant, which was detected at 29% and 30% by the two
pipelines. The remaining three institutions all cited variant not
identified byBI algorithm.One of these institutions added that
for unknown reasons the indel was only observed in onereasons for noncall (No. of times reported)
QC (1), not identified by BI algorithm (1), technical concern (1)
entified by BI algorithm (1)
fied by all
QC (1), below VAF cutoff (1)
QC (1)
entified by BI algorithm (3)
ical concern (1)
577
Davies et alstrand and that a filter rule change allowed it to be detected.
Another site indicated that on exploration of this noncall it
was discovered that it was likely a limitation in their alignment
software (the insertion was observed through manual in-
spection but most of the reads containing the duplication were
apparently not mapped and thus discarded). In the third
instance, no explanation could be determined.
Finally, an ERBB2 exon 20 duplication (c.2311_2322
dupGCATACGTGATG) was detected by four of five in-
stitutions with a VAF range of 34% to 40%. The institution
that did not call this variant explained it as a technical concern
in the discordance report. The insertion was also not observed
aftermanual reviewof the data, but the institution cited known
problems with the alignment and variant calling tools being
used in terms of indel detection.Discussion
Although PT of wet-bench processes for clinical molecular
assays is routine, it is less common for BI and interpretative
processes. However, performing PT on individual assay
components, in this case the postsequencing steps, can help
to isolate potential sources of error. Although usually
assessed during initial assay validation, these quality man-
agement activities are also critical to perform in an ongoing
fashion to ensure assay quality. The findings of this study
exemplify the need for focused postsequencing PT and
demonstrate its feasibility.
The clinical need for postsequencing PT was also high-
lighted by a recent effort spearheaded by CAP to distribute
FASTQ files based on two commonly used library prepa-
ration methods.9 This pilot study demonstrated the feasi-
bility of using existing FASTQ files (in which additional
alterations were manually introduced) for PT and is the
basis for a more widespread availability of this PT option
through CAP. However, this option focused only on two
library preparation methods (the TST kit used in this study
was not one of them), thereby limiting the degree to which
laboratories not using said preparations may be able to
effectively participate. As PT in the arena of BI reaches
increased maturity, additional mechanisms for providing
more widespread approaches will be necessary. This may
include formalized mechanisms for FASTQ file sharing (as
in this study), introduction of variants into existing
FASTQs, and/or distribution of entirely synthetic data for
analysis.
A key component of our PT was the common use of a
single library preparation kit and sequencing method by all
participating sites. This ensured that all variants covered and
reported for any institution would also be variants covered
by the other institutions, thereby eliminating difficulties in
determining whether a noncall was due to a postsequencing
process deficiency or assay design. Another key element of
this study was the use of data generated from actual clinical
tumor specimens. As stated above, an alternative approach578to postsequencing process PT is to use in silico generated
data in which variants are manually added to existing
sequence reads in the FASTQ files. However, in this study,
because sites were asked to report variants as they would for
clinical cases, using data derived from clinical specimens
provided a more realistic basis for the PT and more accu-
rately reflected the spectrum of issues that arise during BI
and interpretative process analysis.
It is perhaps not surprising that, among six institutions
using the same library preparation method, six unique ap-
proaches to bioinformatics analysis and variant interpreta-
tion were used. Within the field of NGS bioinformatics,
numerous tools exist for each technical step (Table 1).
Within these tools are options for customizing parameters
that can affect variant identification. Therefore, even in-
stitutions using similar software components likely use
different settings within these programs, making each BI
pipeline unique in terms of its strengths and weaknesses.
In this study, the reporting of SNVs, particularly those
deemed clinically significant, was highly concordant across
all institutions. However, the reporting of cs-indels was
highly discordant. This finding is consistent with previous
studies that have found significant challenges in the NGS
detection of indels.3,8 Nevertheless, in no instance was it
discovered during this study that a patient was adversely
affected, because parallel testing procedures for indel
detection are in place at the participating institutions
(including parallel BI pipelines that could not be applied to
the externally generated FASTQ files in this study). An
encouraging finding in this study was the low variance of
reported VAF for detected variants. More than 60% of
variants were reported with a range of 1%, and >80%
were reported with a range of 5%. Only four variants (6%)
had VAF ranges >10%. Of the two cs-indels identified by
all participating sites (excluding failed QC samples), one
had a VAF range of 5% and the other had a range of 8%.
For the cs-indels with a higher discordance rate among
laboratories, when the indel was identified, the VAF range
was <10% for all cases. These findings suggest that the
variations in BI processes may often lead to an all or nothing
effect in which the variant is either not reported at all by the
BI pipeline or reported at a consistent VAF. In the few
instances of >10% VAF ranges, these findings may be
directly attributable to specific pipeline differences. For
example, the range of 18% (the largest reported in this
study) observed for a PIK3CA c.3140A>G mutation ap-
pears to be directly attributed to whether sites removed
primer sequences from reads for variant calling purposes (so
that the primer read would not dilute the variant read).
Notably, it has previously been found that variability exits
between BI methods in terms of detection of low frequency
variants.10
The primary purpose of PT is to determine weaknesses or
shortcomings of a procedure and then, if possible, take
corrective action. In this study, we identified indel detection
as a particular shortcoming of several BI pipelines, ajmd.amjpathol.org - The Journal of Molecular Diagnostics
FASTQ-Based NGS Proficiency Testingweakness that is well documented in the literature and was
the basis for requesting indel cases from all sites. As a result
of these discordances being identified, several corrective
actions were implemented, including adjustment of filters,
adjustment of detection scripts, and changing of VAF cut-
offs, all of which resulted in improvement in indel detection
on reanalysis. However, it should be noted that reducing
stringency in BI pipeline components may have the
unwanted effect of reducing specificity (increasing the false-
positive rate). Therefore, adjustments to pipeline compo-
nents designed to improve detection of one type of variant
should always be followed by a revalidation process to fully
characterize the effect of the adjustment across the spectrum
of samples and variant types.
Several solutions to the challenging detection of indels in
NGS data have been proposed. For example, a parallel
pipeline designed specifically for indel detection can be
implemented. A recently published example of an alterna-
tive pipeline that is specific for amplicon-based library
preparation methods directly queries the length of each
amplicon in the assay.11 In theory, an amplicon between two
primers should be an invariable length unless it contains an
insertion or deletion. Changes in amplicon length (longer for
an insertion or shorter for a deletion) are indicative of indels,
flagging the reads to be examined by an indel-specific
annotation program.11
In this study, two sites (sites 1 and 4) identified all cs-
indel cases in the cohort of samples evaluated. Although it
may seem intuitive to suggest that the BI tools used by these
two sites represents a potential for best practices, repro-
duction of simply the tool schemes does not guarantee high
variant detection rates. Within each toolset, customizable
parameters exist, and altering one parameter in one
component may require a compensatory alteration in a
different component. Thus, caution is urged when evalu-
ating the value of individual bioinformatics tools or as-
semblies of tools because careful customization can often be
required. Similarly, pipelines composed of alternate toolsets
can be significantly improved through the custom adjust-
ment of parameters. Therefore, this study in no way estab-
lishes any guidance on the use of individual pipeline tools or
aggregated tools to form a pipeline, although proposed best
practices regarding NGS have been published elsewhere.12
This study also highlights the need for professional so-
ciety guidelines with regard to validation of NGS-based
assays for somatic conditions. Assuredly, the use of well-
designed and high-quality reference materials could be a
foundation for assay validation, and development of such
materials is well under way for a variety of disease types
(eg, through the Genome in a Bottle Consortium). However,
it is inconceivable that any individual or group of reference
standards could be designed to identify every possible flaw
in every possible assay design. Therefore, even with strin-
gent validation criteria, the importance of ongoing PT
cannot be understated. Furthermore, a cornerstone of
maintaining quality in these complex assays is the ability toThe Journal of Molecular Diagnostics - jmd.amjpathol.orgadapt based on weaknesses identified through PT. Thus,
ongoing national-level conversations regarding approaches
for oversight of laboratory testing must account for the
inability to validate every plausible alteration in these as-
says. These conversations must also consider the need for
ongoing flexibility for laboratories to adapt to changing
technology, new information, and feedback from PT.
In conclusion, we reveal the feasibility of applying PT
directly to the postsequencing analysis of NGS data.
Through this process, we identified the detection of clini-
cally significant indels as a particular weakness in several
custom BI pipelines. In many cases, this led directly to
pipeline improvements that enabled the indels to be detected
on reanalysis. Thus, PT based on FASTQ exchange is an
ideal method to assess the performance of BI pipelines and
interpretative processes.
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